更新于：2024-11-01

Idiopathic Polypoidal Choroidal Vasculopathy

特发性息肉样脉络膜血管病

更新于：2024-11-01

基本信息

别名

Idiop polyp choroid vasculpath、Idiopathic Polypoidal Choroidal Vasculopathy、Idiopathic polypoidal choroidal vasculopathy

+ [1]

简介-

关联

项与特发性息肉样脉络膜血管病相关的药物

Avacincaptad pegol

靶点

作用机制

C5抑制剂

在研机构

Astellas Pharma Global Development, Inc. [+2]

原研机构

Ocular Therapeutix, Inc.

在研适应症

地图样萎缩 [+3]

非在研适应症

干性年龄相关性黄斑病变 [+2]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2023-08-04

项与特发性息肉样脉络膜血管病相关的临床试验

NCT02681783 / Unknown status临床4期IIT

PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept

The presence of PEDs in nAMD, CSR and iPCV can present a diagnostic challenge in the elderly population; despite detailed diagnostic testing to differentiate these three conditions, misdiagnosis and mistreatment still occurs. One potential way of differentiating these three conditions might be to compare cytokine profiles in nAMD versus CSR versus iPCV. This information may be useful in creating a diagnostic aqueous cytokine and hormone profile to differentiate between nAMD, CSR and iPCV.
The primary goal of this study is to compare baseline aqueous cytokine and cortisol levels between nAMD, CSR, and iPCV patients and age-matched cataract controls. The secondary objective is to assess intra-group changes in visual and anatomical outcomes in nAMD, CSR and iPCV patients with PED treated with aflibercept and correlate these changes to baseline cytokines.

开始日期2018-12-01

申办/合作机构

Sunnybrook Health Sciences Centre

NCT03374670 / Withdrawn临床2期

A Phase 2A Open-Label Trial to Assess the Safety of ZIMURA™ (Anti-C5) in Combination With EYLEA® in Treatment Experienced Subjects With Idiopathic Polypoidal Choroidal Vasculopathy

To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy

开始日期2018-11-01

申办/合作机构

Ophthotech Corp. (New Jersey)

CTRI/2019/03/017901 / CompletedN/AIIT

Micropulse laser as an adjuvant to antivascular endothelial growth factors in polypoidal choroidal vasculopathy

开始日期2017-11-14

申办/合作机构

L.V. Prasad Eye Institute

100 项与特发性息肉样脉络膜血管病相关的临床结果

登录后查看更多信息

100 项与特发性息肉样脉络膜血管病相关的转化医学

登录后查看更多信息

0 项与特发性息肉样脉络膜血管病相关的专利（医药）

登录后查看更多信息

122

项与特发性息肉样脉络膜血管病相关的文献（医药）

2024-08-01·Indian Journal of Ophthalmology

Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group

Article

作者: Agarwal, Manisha ; Chakraborty, Debdulal ; Pillai, Gopal S ; Muralidhar, Alankrita ; Chakraborty, Somnath ; Koundanya, Vikram ; Arora, Anshu ; Gopalakrishnan, Mahesh ; Patil, Sanket ; Dudani, Ajay ; Maiti, Aniruddha ; Shanmugam, Mahesh P ; Verma, Lalit ; Choudhary, Shailender ; Natesh, Sribhargava ; Shroff, Darius ; Mishra, Sanjay K ; Jayadev, Chaitra ; Kothari, Abhishek ; Narayanan, Raja ; Gupta, Charu ; Lahiri, Kairobi ; Aggarwal, Vinod

Context:Concerns about brolucizumab’s (Pagenax®) association with intraocular inflammation (IOI) limit its use despite its cost-effectiveness and efficacy. This multicentric study analyzes IOI incidence across 21 tertiary eyecare centers in India since its introduction in October 2020.Purpose:To determine the real-world incidence rate of IOI in Indian patients secondary to intravitreal brolucizumab across 21 tertiary eye care centers in India.Settings and Design:Retrospective multicentric, survey-based study.Methods:Data including number of patients treated, clinical indications, side effects encountered, and IOI case details was collected via Google Forms in 21 Indian tertiary eye care centers since October 2020. Mean, median, frequency, and standard deviation were calculated for statistical analysis.Results:All centers used pro re nata protocol for brolucizumab injections with a minimum injection interval of 8 weeks. The incidence of IOI was 0.79% (21 events out of 2655 eyes). Treatment indications included idiopathic polypoidal choroidal vasculopathy, neovascular age-related macular degeneration, diabetic macular edema, and off-label uses. IOI was experienced after the first injection (57%) in majority of cases with a median onset of 14 days (range: 1–65 days). IOI was mild in 28.5%, moderate in 33%, and severe in 38% of cases. Eighteen out of 21 IOI eyes recovered preinjection best corrected visual acuity or better.Conclusions:Our study found a lower IOI incidence (0.79%) with brolucizumab (Pagenax) in Indian patients compared to previously reported literature. IOI events were mostly mild to moderate, and post-treatment, most patients improved or maintained BCVA. Larger prospective multicentric studies with PRN dosing protocol are needed to confirm these findings.

2024-07-11·[Zhonghua yan ke za zhi] Chinese journal of ophthalmology

[Ophthalmic surgical robot-assisted retinal puncture and injection for submacular hemorrhage caused by polypoid choroidal vasculopathy: a case report].

Article

作者: Yu, J F ; Cui, D ; Zhou, M C ; Ye, X ; Chen, H ; Shen, L J ; Chen, Y Q

1例65岁左眼视力下降1个月男性患者，经超广角眼底检查、相干光层析成像术和B超检查，临床诊断为左眼特发性息肉状脉络膜血管病变致出血性视网膜脱离（黄斑下出血），行玻璃体切除联合眼科手术机器人辅助视网膜穿刺注药术，术中眼科手术机器人通过超精细微型注射针将约0.2 ml阿替普酶精准注入视网膜神经上皮与色素上皮之间。术后随访2个月，黄斑下出血体征明显改善，左眼视力由术前的眼前手动提高至0.1，未见其他并发症，手术效果满意。（本文于2024年3月15日优先出版在中华眼科杂志官网）.

2024-01-01·Indian Journal of Ophthalmology

Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile

Article

作者: Khatri, Manoj G ; Rajan, Mohan ; Dabir, Supriya ; Mohankumar, Arthi

Background:Brolucizumab is a new anti-vascular endothelial growth factor (anti-VEGF) in the treatment of neovascular age-related macular degeneration (nAMD) and idiopathic polypoidal choroidal vasculopathy (IPCV).Materials and Methods:A retrospective, consecutive, interventional study was conducted from a tertiary eye hospital, in which treatment-naïve and treatment-switch patients were included. They underwent an intravitreal injection of brolucizumab. The decision to reinject was made based on the presence of fluid on spectral domain optical coherence tomography (SD-OCT) or worsening of vision at follow-up. Outcome measures were changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), fluid (subretinal/intraretinal/sub-retinal pigment epithelium fluid) levels, and OCT biomarkers and safety analysis.Results:A total of 59 eyes of 50 patients with a total of 132 intravitreal injections were included. There was a statistically significant improvement (P < 0.05) in BCVA from baseline in logMAR treatment-naïve patients (mean BCVA at baseline 0.6 ± 0.41 and 0.37 ± 0.56). The mean baseline CST of all patients significantly reduced from 582.92 ± 233.11 µm at baseline to 474.06 ± 252.89 µm at the final treatment visit. Thirty-eight percent of patients showed complete resolution of SHRM after a single injection. The interval between each subsequent injection increased from a mean of 67 to 96 days in treatment-switch patients and from 47 to 151 days in treatment-naïve patients.Conclusion:Brolucizumab promises reduced number of injections with longer treatment intervals.